New Orleans Doctor Gets Prostate Cancer Drug Approved

A New Orleans oncologist's three-decade mission just changed the game for men facing prostate cancer.

Dr. Oliver Sartor helped bring Pluvicto to the United States, a treatment that targets cancer cells while leaving healthy tissue alone. Instead of chemotherapy's "poison in the bathwater" approach that damages everything it touches, this therapy uses radioactive isotopes that home in on cancer like a guided missile.

Sartor started researching this approach in 1994 at the National Cancer Institute. The treatment originated in Germany, but he worked to get it into American trials and ultimately to FDA approval.

On July 31, 2024, the FDA approved Pluvicto for upfront treatment of metastatic prostate cancer. Patients no longer need to endure hormone therapy or chemotherapy first. They can now access this targeted treatment immediately after diagnosis.

"This provides an opportunity to get a positive effect on the patient, but without using the chemotherapy and those side effects," Sartor said.

The doctor's career has been a Louisiana homecoming story. After training at the National Cancer Institute in Maryland, he returned to be near his parents. He built cancer research programs at LSU, spent 17 years at Tulane, and even came back after Hurricane Katrina forced a brief Harvard stint.

Last June, he launched the Transformational Prostate Cancer Research Center at East Jefferson Hospital with LCMC Health. The hospital invested in a state-of-the-art PET scanner specifically for his work. They hired his entire research team and gave him the space to continue developing novel therapies.

Now Sartor sees patients twice weekly while running clinical trials for men who've exhausted standard treatments. He's also identifying families with genetic predispositions to prostate cancer, catching the disease earlier when cure rates are highest.

The Ripple Effect

Sartor's persistence created a ripple that reaches far beyond Louisiana. Pluvicto has earned five FDA approvals total, including three separate indications for prostate cancer. Each approval opens the door for more patients to skip chemotherapy's brutal side effects.

His work on early detection through genetic testing means sons of his patients can be monitored closely. If cancer appears, it's caught when treatment options are abundant and cure is most likely.

The targeted approach he championed for 30 years is now changing how oncologists think about cancer treatment across multiple disease types.

One doctor's refusal to give up on a better way forward just gave thousands of men a fighting chance with their dignity intact.